Late Breaking Data: Lebrikizumab Demonstrates Efficacy in AD Patients with Skin of Color
Eli Lilly revealed promising results for lebrikizumab in treating atopic dermatitis in patients with skin of color at the RAD 2025 conference.
Related Articles
Mohs Surgery vs Wide Local Excision in Primary High-Stage Cutaneous Squamous Cell Carcinoma
This cohort study assesses the outcomes of primary high-stage cutaneous squamous cell carcinoma among patients treated with Mohs surgery compared with those treated with wide…
Psoriasis and Hidden Inflammation: A Cardiovascular Risk Uncovered
Discover a study in which researchers examined three international cohorts of patients with moderate-to-severe psoriasis undergoing biologic therapy.
Recognizing Topical Steroid Withdrawal and Advancing Therapeutic Precision
At RAD 2025, Brad Glick, DO, MPH, reviewed the clinical signs of topical steroid withdrawal, the need for detailed patient histories to distinguish it from…
Late-Breaking Data: Real-World Data from Canada Shows Upadacitinib is Effective in Patients With Moderate to Severe AD With Inadequate Response to Dupilumab
At RAD 2025, Vimal H. Prajapati, MD, shared phase 4 data from the CAN UpTIMISE study that shows switching to upadacitinib after inadequate response with…
Dupilumab Shows Long-Term Efficacy in Children with Type 2 Asthma, Regardless of Allergy Status
A long-term study shows that dupilumab significantly reduces asthma exacerbations in children with type 2 asthma, offering sustained benefits for both allergic and non-allergic patients.
Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors
This cohort study describes the morphologic classification, histopathologic characteristics, treatments, and outcomes of chronic cutaneous immune-related adverse events occurring in adjuvant or metastatic setting.
Chronic Itch Pathophysiology and Therapeutic Advances
At the 2025 Revolutionizing Atopic Dermatitis Conference, Gil Yosipovitch, MD, explored the pathophysiology of chronic itch through the lens of type 2 cytokine inhibition, neuromodulatory…
Day 2 Recap: 2025 Revolutionizing Atopic Dermatitis Conference
Catch up on coverage from the final day of the 2025 Revolutionizing Atopic Dermatitis Conference held in Nashville, Tennessee.
Tripe Palms
This case report describes a woman in her 60s with smoking history, chronic productive cough, weight loss, and asymptomatic thickening of the palmar skin.